41 – 50 of 139
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF
- Contribution to journal › Article
- 2019
-
Mark
PDGF-B Is Required for Development of the Glymphatic System
- Contribution to journal › Article
-
Mark
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
- Contribution to journal › Scientific review
-
Mark
Novel tau fragments in cerebrospinal fluid : relation to tangle pathology and cognitive decline in Alzheimer’s disease
- Contribution to journal › Article
-
Mark
Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease : Cross-validation study of practical algorithms
- Contribution to journal › Article
-
Mark
Cisterna Magna Injection in Rats to Study Glymphatic Function
- Contribution to journal › Article
-
Mark
Towards a unified protocol for handling of CSF before β-amyloid measurements
- Contribution to journal › Article
-
Mark
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
- Contribution to journal › Article
-
Mark
α-synuclein−lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson’s disease patients
(2019) In Proceedings of the National Academy of Sciences of the United States of America 116(30). p.15226-15235
- Contribution to journal › Article
-
Mark
Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS
- Contribution to journal › Article
